Cross-Sector entity
Of the tracked stories, 2 of 2 also mention CDC National Center for Injury Prevention and Control, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category.
2 verified stories tracked
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention CDC National Center for Injury Prevention and Control, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. Cannabis Hyperemesis Syndrome appears in 2 tracked Cross-Sector stories from August 7, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cannabis Hyperemesis Syndrome. Shared-story counts are live from our verified record — not editorial picks.
The introduction of a dedicated ICD-10 code for cannabis hyperemesis syndrome triggered a 16% jump in emergency department diagnoses, unmasking a massive hidden burden on U.S. hospitals. With 200,000 prior ED visits and 2.75 million annual sufferers, health systems must now manage increased demand, train clinicians, and integrate the new code into EHRs and population health analytics.
With 2.75 million suffering from cannabis hyperemesis syndrome and a 16% jump in ED diagnoses after a new ICD code, an underserved patient population emerges. Biopharma companies can explore targeted therapies for CHS, a condition currently managed only with abstinence and supportive care, presenting a significant unmet medical need.
Source: troyrecord.com · MedPage Today
